The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMedium•12 March 2026•

1 min read

Grifols Rated 'BUY' as Net Profit Surges 150% Amid Successful Debt Reduction

Canadian flag, a plasma bag, and "GRIFOLS" text on an orange background with medical equipment, microscopes, and vials.

Key Facts

1Grifols is rated 'BUY' with a €20/share price target and $23/share ADR target.

2The company delivered €450M in cost savings and 150%+ net profit growth.

Grifols (GRFS) has received a 'BUY' rating from analysts following a robust financial performance and a successful execution of its turnaround strategy. The company reported a net profit growth exceeding 150%, bolstered by significant cost savings totaling €450 million. Operational efficiency has improved markedly, with free cash flow (FCF) surpassing previous guidance and leverage falling to 4.2x. Consequently, analysts have set a price target of €20 per share for its Spanish listing and $23 for its American Depositary Receipts (ADRs). This positive outlook is driven by the company's ability to generate strong cash flow and its clear path toward further debt reduction. Despite its current BB- credit rating, the reinstatement of dividends and improved fundamentals signal a strong recovery for the healthcare giant.